NuVasive Company Profile (NASDAQ:NUVA)

About NuVasive (NASDAQ:NUVA)

NuVasive logoNuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process. Its principal product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The platform includes its software-driven nerve detection and avoidance systems, including NVM5, and intraoperative monitoring services and support; MaXcess, an integrated split-blade retractor system, and a range of implants and biologics. The platform combines three product categories: its MaXcess retractors, specialized implants and fixation products, and nerve monitoring systems and service offerings that collectively enable surgeons to detect and navigate around nerves, while directing customized access to the spine for implant delivery.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:NUVA
  • CUSIP: 67070410
  • Web:
  • Market Cap: $2.77236 billion
  • Outstanding Shares: 50,804,000
Average Prices:
  • 50 Day Moving Avg: $56.02
  • 200 Day Moving Avg: $68.65
  • 52 Week Range: $49.25 - $81.68
  • Trailing P/E Ratio: 86.69
  • Foreward P/E Ratio: 22.94
  • P/E Growth: 1.88
Sales & Book Value:
  • Annual Revenue: $1.02 billion
  • Price / Sales: 2.74
  • Book Value: $13.54 per share
  • Price / Book: 4.07
  • EBITDA: $225.78 million
  • Net Margins: 3.50%
  • Return on Equity: 13.04%
  • Return on Assets: 5.81%
  • Debt-to-Equity Ratio: 0.79%
  • Current Ratio: 2.40%
  • Quick Ratio: 1.44%
  • Average Volume: 1.40 million shs.
  • Beta: 1.03
  • Short Ratio: 6.9

Frequently Asked Questions for NuVasive (NASDAQ:NUVA)

What is NuVasive's stock symbol?

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

How were NuVasive's earnings last quarter?

NuVasive, Inc. (NASDAQ:NUVA) released its quarterly earnings data on Thursday, July, 27th. The company reported $0.46 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.44 by $0.02. The company earned $260.60 million during the quarter, compared to the consensus estimate of $261.95 million. NuVasive had a net margin of 3.50% and a return on equity of 13.04%. NuVasive's revenue for the quarter was up 10.3% on a year-over-year basis. During the same period last year, the firm earned $0.40 EPS. View NuVasive's Earnings History.

When will NuVasive make its next earnings announcement?

NuVasive is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for NuVasive.

What guidance has NuVasive issued on next quarter's earnings?

NuVasive updated its FY17 earnings guidance on Thursday, July, 27th. The company provided earnings per share (EPS) guidance of $2.00 for the period, compared to the Thomson Reuters consensus estimate of $2.01. The company issued revenue guidance of $1.065 billion, compared to the consensus revenue estimate of $1.07 billion.

Where is NuVasive's stock going? Where will NuVasive's stock price be in 2017?

14 analysts have issued 12 month price targets for NuVasive's stock. Their predictions range from $60.00 to $90.00. On average, they expect NuVasive's share price to reach $74.00 in the next year. View Analyst Ratings for NuVasive.

What are analysts saying about NuVasive stock?

Here are some recent quotes from research analysts about NuVasive stock:

  • 1. According to Zacks Investment Research, "NuVasive’s second-quarter 2017 performance was mixed with the bottom line beating the estimates and sales missing the mark. However, year-over-year, revenue growth was solid, led by robust performance in the international market on above-market growth across all geographies. Notably, over the recent past, the company has demonstrated steady year-over-year improvement on the top-line front on account of strong procedural growth in the U.S. as well as internationally. We are optimistic about the company’s recent progress in development of technologies and services for spine surgery. On the flip side, over the last three months, NuVasive has been trading below the broader industry. Further, currency headwind, pricing and reimbursement issues along with a competitive landscape are major downsides. Also, the company’s low-margin Biotronic business impacted the second quarter’s performance." (7/31/2017)
  • 2. Needham & Company LLC analysts commented, "NUVA’s 2Q17 revenue missed and EPS beat consensus and management maintained its 2017 guidance. Pro forma revenue growth slowed to 5% in 2Q17 from 6% in 1Q17 as biologics sales continued to decline and operational challenges arose from the relocation of a neuromonitoring billing and collection department. NUVA’s operating margin beat consensus and increased 40 bps Y/Y. Despite NUVA’s slower revenue growth, management still expects revenue growth to accelerate in 2H17 given easier comps, new products, new customer wins, and new sales reps coming off non-competes." (7/28/2017)
  • 3. Canaccord Genuity analysts commented, "We note leading indicators of forward growth — new product flow (Less-ray, cervical iGA, Unite, pediatric deformity, expandable cages) and sales rep additions (+15 percent Y/Y in 2016) — should drive incremental growth opportunities entering the H2/16," the analyst said.On Track to Deliver Meaningful LeverageCanaccord Genuity believes the company is on track to deliver meaningful leverage over the next five years, although it expects M&A and continued investments to offset near-term improvements in operating margins."In sum, we continue to view the margin story positively but expect 2017 to be back-end loaded as NUVA realizes the benefits of sales force investments (building out peds team) and marketing efforts in Japan," the firm said.Guidance Reflects Changing SeasonalityThe firm noted that the company guided full-year revenues to $1.065 million, including a $10 million forex headwind, adjusted operating margins of 17.1 percent, up 100 basis points year-over-year, and earnings of $2 per share. However, the second quarter revenue guidance of $262 million was about $5 million below the consensus estimate, the firm added.According to the firm, this reflects the changing seasonality of the revenue cadence post the Ellipse Biotronic acquisitions. Concluding, the firm said, "We continue to believe that NuVasive is in prime share-taking position in the global spine market, driven by innovative new product flow, robust sales force additions, and broader tailwinds such as vendor consolidation."Furthermore, the margin expansion story remains intact and we see upside bias to estimates despite the second-half weighted guidance." (4/26/2017)
  • 4. UBS AG analysts commented, "The company's long-term operating margin goal of 25% was a key topic of discussion last week when we hosted NUVA for investor meetings. Management laid out a clear pathway to 25% operating margins (from 16.1% currently), which included: 1) 400 bps from in-source manufacturing; 2) 400 bps from asset efficiencies; 3) 400 bps from OUS scalability; and 4) 200 bps from sales force efficiencies, offset by 500 bps of R&D investment and pricing headwinds. We reiterate our Buy rating on NUVA and $82 price target and expect consistent execution and margin improvements to drive the stock higher." (3/20/2017)

Who are some of NuVasive's key competitors?

Who are NuVasive's key executives?

NuVasive's management team includes the folowing people:

  • Gregory T. Lucier, Chairman of the Board, Chief Executive Officer
  • Rajesh J. Asarpota, Chief Financial Officer, Executive Vice President
  • Joan B. Stafslien, Executive Vice President, General Counsel, Corporate Secretary
  • Carol A. Cox, Executive Vice President - External Affairs and Corporate Marketing
  • Peter Michael Leddy Ph.D., Executive Vice President, Global Human Resources, Integrations, Real Estate and Internal Communications
  • Matthew W. Link, Executive Vice President - Strategy, Technology and Corporate Development
  • Stephen Rozow, - Global Process Transformation
  • Vickie L. Capps, Independent Director
  • Peter C. Farrell Ph.D., Independent Director
  • Robert F. Friel, Independent Director

Who owns NuVasive stock?

NuVasive's stock is owned by many different of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (2.57%), Mutual of America Capital Management LLC (0.12%), State Treasurer State of Michigan (0.04%) and Quantitative Systematic Strategies LLC (0.02%). Company insiders that own NuVasive stock include Gregory T Lucier, Jason Hannon, Joan Stafslien, Lesley H Howe, Matthew Link, Michael D Ohalleran, Patrick Miles, Peter Michael Leddy and Quentin S Blackford. View Institutional Ownership Trends for NuVasive.

Who sold NuVasive stock? Who is selling NuVasive stock?

NuVasive's stock was sold by a variety of institutional investors in the last quarter, including Mutual of America Capital Management LLC, Fisher Asset Management LLC and State Treasurer State of Michigan. Company insiders that have sold NuVasive stock in the last year include Jason Hannon, Lesley H Howe and Matthew Link. View Insider Buying and Selling for NuVasive.

Who bought NuVasive stock? Who is buying NuVasive stock?

NuVasive's stock was acquired by a variety of institutional investors in the last quarter, including Quantitative Systematic Strategies LLC. Company insiders that have bought NuVasive stock in the last two years include Gregory T Lucier, Joan Stafslien, Michael D Ohalleran, Patrick Miles and Peter Michael Leddy. View Insider Buying and Selling for NuVasive.

How do I buy NuVasive stock?

Shares of NuVasive can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NuVasive's stock price today?

One share of NuVasive stock can currently be purchased for approximately $55.05.

MarketBeat Community Rating for NuVasive (NASDAQ NUVA)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  504 (Vote Outperform)
Underperform Votes:  403 (Vote Underperform)
Total Votes:  907
MarketBeat's community ratings are surveys of what our community members think about NuVasive and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for NuVasive (NASDAQ:NUVA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 11 Buy Ratings
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $74.00 (34.42% upside)
Consensus Price Target History for NuVasive (NASDAQ:NUVA)
Price Target History for NuVasive (NASDAQ:NUVA)
Analysts' Ratings History for NuVasive (NASDAQ:NUVA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/19/2017Barclays PLCLower Price TargetOverweight$80.00 -> $65.00N/AView Rating Details
10/12/2017Robert W. BairdSet Price TargetHold$72.00 -> $60.00N/AView Rating Details
10/12/2017Cowen and CompanySet Price TargetBuy$72.00N/AView Rating Details
10/12/2017Leerink SwannReiterated RatingOutperform$74.00 -> $69.00N/AView Rating Details
10/10/2017Royal Bank Of CanadaReiterated RatingBuy$75.00N/AView Rating Details
10/6/2017Needham & Company LLCReiterated RatingSellN/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingEqual Weight$81.00 -> $70.00N/AView Rating Details
10/4/2017BTIG ResearchReiterated RatingBuy$82.00 -> $74.00N/AView Rating Details
10/3/2017Jefferies Group LLCReiterated RatingBuy$79.00LowView Rating Details
9/28/2017Piper Jaffray CompaniesReiterated RatingBuy$90.00LowView Rating Details
9/21/2017GabelliReiterated RatingBuyLowView Rating Details
7/28/2017Canaccord GenuityReiterated RatingBuy$80.00LowView Rating Details
4/11/2017BMO Capital MarketsReiterated RatingBuy$82.00LowView Rating Details
11/30/2016AegisInitiated CoverageBuy$72.00N/AView Rating Details
7/27/2016Brean CapitalBoost Price TargetBuy$60.00 -> $70.00N/AView Rating Details
7/13/2016J P Morgan Chase & CoUpgradeNeutral -> Overweight$55.00 -> $74.00N/AView Rating Details
12/11/2015Bank of America CorporationUpgradeUnderperform -> Neutral$56.00N/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for NuVasive (NASDAQ:NUVA)
Earnings by Quarter for NuVasive (NASDAQ:NUVA)
Earnings History by Quarter for NuVasive (NASDAQ NUVA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/23/2017$0.50N/AView Earnings Details
7/27/2017Q2 2017$0.44$0.46$261.95 million$260.60 millionViewN/AView Earnings Details
4/25/2017Q1 2017$0.37$0.38$250.52 million$249.86 millionViewN/AView Earnings Details
2/9/2017Q416$0.51$0.53$261.25 million$271.10 millionViewListenView Earnings Details
10/25/2016Q316$0.40$0.40$243.49 million$239.60 millionViewListenView Earnings Details
7/26/2016Q216$0.36$0.40$232.86 million$236.50 millionViewListenView Earnings Details
4/26/2016Q116$0.27$0.31$205.54 million$215.10 millionViewListenView Earnings Details
2/11/2016Q415$0.31$0.35$215.08 million$215.30 millionViewListenView Earnings Details
10/27/2015Q315$0.27$0.35$200.21 million$200.50 millionViewListenView Earnings Details
7/28/2015Q215$0.25$0.31$200.71 million$202.91 millionViewListenView Earnings Details
5/4/2015Q115$0.21$0.30$189.30 million$192.40 millionViewListenView Earnings Details
2/24/2015Q4$0.37$0.39$201.40 million$204.30 millionViewListenView Earnings Details
10/30/2014Q314$0.14$0.09$179.30 million$189.90 millionViewListenView Earnings Details
7/29/2014Q214$0.25$0.28$177.50 million$190.70 millionViewListenView Earnings Details
4/29/2014Q114$0.13$0.29$171.30 million$177.50 millionViewListenView Earnings Details
3/3/2014Q413$0.32$0.37$181.24 million$190.80 millionViewListenView Earnings Details
10/29/2013Q313$0.24$0.39$158.30 million$169.20 millionViewListenView Earnings Details
7/30/2013Q2 2013$0.23$0.20$161.67 million$165.70 millionViewListenView Earnings Details
4/30/2013Q1 2013$0.22$0.26$157.34 million$159.50 millionViewListenView Earnings Details
2/26/2013Q4 2012$0.21$0.34$156.35 million$165.80 millionViewListenView Earnings Details
10/24/2012$0.21$0.23ViewN/AView Earnings Details
7/25/2012$0.23$0.27ViewN/AView Earnings Details
4/30/2012$0.18$0.20ViewN/AView Earnings Details
2/22/2012$0.22$0.27ViewN/AView Earnings Details
10/27/2011$0.24$0.26ViewN/AView Earnings Details
7/25/2011$0.28$0.30ViewN/AView Earnings Details
5/5/2011$0.19$0.24ViewN/AView Earnings Details
2/23/2011$0.42$0.46ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for NuVasive (NASDAQ:NUVA)
2017 EPS Consensus Estimate: $2.00
2018 EPS Consensus Estimate: $2.46
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.37$0.39$0.38
Q2 20173$0.44$0.48$0.46
Q3 20173$0.44$0.55$0.50
Q4 20173$0.64$0.66$0.65
Q1 20182$0.45$0.57$0.51
Q2 20182$0.58$0.61$0.60
Q3 20182$0.60$0.64$0.62
Q4 20182$0.69$0.78$0.74
(Data provided by Zacks Investment Research)


Dividend History for NuVasive (NASDAQ:NUVA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for NuVasive (NASDAQ:NUVA)
Insider Ownership Percentage: 1.20%
Insider Trades by Quarter for NuVasive (NASDAQ:NUVA)
Institutional Ownership by Quarter for NuVasive (NASDAQ:NUVA)
Insider Trades by Quarter for NuVasive (NASDAQ:NUVA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/29/2017Gregory T LucierCEOBuy2,000$61.52$123,040.00View SEC Filing  
8/18/2017Lesley H. HoweDirectorSell3,970$64.64$256,620.80View SEC Filing  
8/17/2017Gregory T LucierCEOBuy5,000$66.22$331,100.00View SEC Filing  
8/1/2017Peter Michael LeddyEVPBuy7,850$63.88$501,458.00View SEC Filing  
3/8/2017Jason HannonInsiderSell24,840$74.22$1,843,624.80View SEC Filing  
2/14/2017Lesley H. HoweDirectorSell6,049$73.26$443,149.74View SEC Filing  
12/12/2016Matthew LinkInsiderSell10,303$67.99$700,500.97View SEC Filing  
11/4/2016Michael D OhalleranDirectorBuy4,200$58.26$244,692.00View SEC Filing  
11/2/2016Patrick MilesDirectorBuy16,967$58.97$1,000,543.99View SEC Filing  
11/1/2016Patrick MilesDirectorBuy16,667$59.00$983,353.00View SEC Filing  
10/31/2016Joan StafslienEVPBuy5,000$59.68$298,400.00View SEC Filing  
10/31/2016Michael D OhalleranDirectorBuy4,205$59.47$250,071.35View SEC Filing  
8/23/2016Jason HannonEVPSell2,625$64.80$170,100.00View SEC Filing  
8/2/2016Jason HannonEVPSell11,184$62.70$701,236.80View SEC Filing  
8/2/2016Lesley H. HoweDirectorSell3,602$62.44$224,908.88View SEC Filing  
7/20/2016Jason HannonEVPSell2,920$62.80$183,376.00View SEC Filing  
6/16/2016Jason HannonEVPSell14,534$57.57$836,722.38View SEC Filing  
1/6/2016Patrick MilesCOOSell10,723$54.03$579,363.69View SEC Filing  
12/16/2015Patrick MilesCOOSell9,127$52.56$479,715.12View SEC Filing  
12/7/2015Quentin S BlackfordCFOSell15,000$51.10$766,500.00View SEC Filing  
12/3/2015Patrick MilesCOOSell5,873$52.51$308,391.23View SEC Filing  
11/2/2015Patrick MilesCOOSell15,000$48.12$721,800.00View SEC Filing  
10/5/2015Matthew LinkinsiderSell1,714$50.72$86,934.08View SEC Filing  
10/3/2015Quentin S BlackfordCFOSell5,000$36.30$181,500.00View SEC Filing  
10/1/2015Patrick MilesCOOSell15,000$48.10$721,500.00View SEC Filing  
9/8/2015Russell PowersEVPSell5,806$51.64$299,821.84View SEC Filing  
9/2/2015Jason HannonEVPSell11,962$52.02$622,263.24View SEC Filing  
9/1/2015Patrick MilesCOOSell15,000$52.03$780,450.00View SEC Filing  
8/31/2015Patrick MilesCOOSell15,000$53.34$800,100.00View SEC Filing  
7/20/2015Jason HannonEVPSell15,000$49.60$744,000.00View SEC Filing  
6/15/2015Gregory T LucierCEOBuy4,491$49.49$222,259.59View SEC Filing  
6/12/2015Gregory T LucierCEOBuy8,000$50.10$400,800.00View SEC Filing  
6/10/2015Gregory T LucierCEOBuy10,000$49.10$491,000.00View SEC Filing  
6/8/2015Gregory T LucierCEOBuy10,000$49.26$492,600.00View SEC Filing  
6/4/2015Gregory T LucierCEOBuy10,000$49.71$497,100.00View SEC Filing  
6/2/2015Gregory T LucierCEOBuy8,000$49.96$399,680.00View SEC Filing  
6/2/2015Patrick MilesCOOSell4,194$49.47$207,477.18View SEC Filing  
5/29/2015Jack R BlairDirectorSell3,703$50.16$185,742.48View SEC Filing  
5/28/2015Gregory T LucierCEOBuy34,000$49.25$1,674,500.00View SEC Filing  
5/28/2015Russell PowersEVPSell8,042$49.00$394,058.00View SEC Filing  
5/19/2015Patrick MilesCOOSell15,000$47.52$712,800.00View SEC Filing  
5/1/2015Russell PowersEVPSell11,881$45.21$537,140.01View SEC Filing  
4/24/2015Russell PowersEVPSell3,888$44.07$171,344.16View SEC Filing  
3/13/2015Patrick MilesCOOSell7,920$45.52$360,518.40View SEC Filing  
3/9/2015Alexis V LukianovCEOSell5,313$44.82$238,128.66View SEC Filing  
3/3/2015Matthew LinkInsiderSell7,500$44.46$333,450.00View SEC Filing  
3/2/2015Jason HannonEVPSell5,085$45.06$229,130.10View SEC Filing  
2/9/2015Alexis V LukianovCEOSell5,454$46.10$251,429.40View SEC Filing  
2/5/2015Matthew LinkInsiderSell4,078$45.77$186,650.06View SEC Filing  
2/3/2015Patrick MilesCOOSell15,000$45.53$682,950.00View SEC Filing  
1/28/2015Keith ValentineCOOSell6,970$46.96$327,311.20View SEC Filing  
1/12/2015Alexis V LukianovCEOSell7,452$49.69$370,289.88View SEC Filing  
1/5/2015Jason HannonEVPSell12,117$46.82$567,317.94View SEC Filing  
1/5/2015Patrick MilesInsiderSell15,000$46.61$699,150.00View SEC Filing  
12/30/2014Jason HannonEVPSell15,000$47.63$714,450.00View SEC Filing  
12/29/2014Jason HannonEVPSell3,146$47.57$149,655.22View SEC Filing  
12/24/2014Patrick MilesInsiderSell15,000$47.52$712,800.00View SEC Filing  
12/19/2014Keith ValentineCOOSell5,893$47.78$281,567.54View SEC Filing  
12/1/2014Keith ValentineCOOSell2,500$43.66$109,150.00View SEC Filing  
11/19/2014Keith ValentineCOOSell5,582$43.32$241,812.24View SEC Filing  
11/19/2014Quentin S BlackfordCFOSell7,698$43.41$334,170.18View SEC Filing  
11/7/2014Alexis V LukianovCEOSell25,000$41.40$1,035,000.00View SEC Filing  
11/3/2014Keith ValentineCOOSell2,500$40.61$101,525.00View SEC Filing  
10/2/2014Keith ValentineCOOSell2,500$35.00$87,500.00View SEC Filing  
9/2/2014Keith ValentineCOOSell2,500$35.14$87,850.00View SEC Filing  
8/1/2014Keith ValentineCOOSell2,500$37.11$92,775.00View SEC Filing  
8/1/2014Michael LambertCFOSell4,010$37.11$148,811.10View SEC Filing  
7/30/2014Jason HannonEVPSell5,000$39.00$195,000.00View SEC Filing  
7/10/2014Russell PowersEVPSell3,200$33.43$106,976.00View SEC Filing  
7/1/2014Keith ValentineCOOSell2,500$35.65$89,125.00View SEC Filing  
7/1/2014Michael LambertCFOSell23,225$35.48$824,023.00View SEC Filing  
6/20/2014Keith ValentineCOOSell5,000$35.00$175,000.00View SEC Filing  
6/20/2014Russell PowersEVPSell9,526$35.00$333,410.00View SEC Filing  
5/5/2014Robert HuntDirectorSell20,000$34.25$685,000.00View SEC Filing  
5/2/2014Michael LambertCFOSell13,096$33.07$433,084.72View SEC Filing  
4/1/2014Keith ValentineCOOSell2,500$38.41$96,025.00View SEC Filing  
3/11/2014Peter FarrellDirectorSell48,000$36.88$1,770,240.00View SEC Filing  
1/21/2014Jason HannonEVPSell10,095$36.60$369,477.00View SEC Filing  
1/16/2014Keith ValentineCOOSell20,000$37.96$759,200.00View SEC Filing  
1/7/2014Alexis LukianovCEOSell34,217$34.29$1,173,300.93View SEC Filing  
1/7/2014Craig HunsakerSVPSell4,980$35.00$174,300.00View SEC Filing  
12/30/2013Craig HunsakerSVPSell4,275$32.10$137,227.50View SEC Filing  
12/23/2013Michael LambertCFOSell17,091$32.49$555,286.59View SEC Filing  
11/7/2013Alexis LukianovCEOSell5,000$31.45$157,250.00View SEC Filing  
10/30/2013Jason HannonEVPSell2,334$28.90$67,452.60View SEC Filing  
10/30/2013Patrick MilesInsiderSell21,223$31.10$660,035.30View SEC Filing  
10/28/2013Patrick MilesInsiderSell7,331$25.72$188,553.32View SEC Filing  
10/21/2013Russell PowersVPSell12,500$25.39$317,375.00View SEC Filing  
10/11/2013Jason HannonEVPSell1,000$26.00$26,000.00View SEC Filing  
10/7/2013Jason HannonEVPSell8,705$23.99$208,832.95View SEC Filing  
10/7/2013Michael LambertCFOSell15,442$24.04$371,225.68View SEC Filing  
8/6/2013Richard Treharne IIIDirectorBuy2,000$23.26$46,520.00View SEC Filing  
7/12/2013Craig E HunsakerSVPSell2,000$27.00$54,000.00View SEC Filing  
7/8/2013Alexis V LukianovCEOSell5,000$25.74$128,700.00View SEC Filing  
7/1/2013Keith ValentineCOOSell1,698$25.00$42,450.00View SEC Filing  
5/13/2013Alexis V LukianovCEOSell7,500$22.71$170,325.00View SEC Filing  
5/8/2013Peter Michael LeddyDirectorBuy2,400$22.24$53,376.00View SEC Filing  
5/7/2013Alexis V LukianovCEOSell12,500$22.11$276,375.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for NuVasive (NASDAQ:NUVA)
Latest Headlines for NuVasive (NASDAQ:NUVA)
DateHeadline logoNuVasive's TLX Interbody System Gets Expanded FDA Approval - October 20 at 6:58 AM logoNuVasive, Inc. (NUVA) Rating Reiterated by Barclays PLC - October 19 at 6:58 PM logoNuVasive Launches New 3D-Printed Porous Titanium Implant In Expanding Advanced Materials Science Portfolio - PR Newswire (press release) - October 19 at 7:00 AM logoNuVasive Launches New 3D-Printed Porous Titanium Implant In Expanding Advanced Materials Science Portfolio - October 19 at 7:00 AM logoNuVasive Receives Expanded FDA 510(k) Clearance For TLX Interbody System Used In TLIF Procedures - PR Newswire (press release) - October 18 at 7:45 AM logoNuVasive (NUVA) vs. Its Peers Head to Head Review - October 18 at 6:36 AM logoNuVasive (NUVA) Reports Expanded FDA 510(k) Clearance For TLX Interbody System Used In TLIF Procedures - October 17 at 3:21 AM logoNuVasive Gets Expanded FDA Clearance For TLX Interbody System Used In TLIF - October 17 at 3:21 AM logoNuVasive Receives Expanded FDA 510(k) Clearance For TLX Interbody System Used In TLIF Procedures - October 17 at 3:21 AM logoNuVasive, Inc. (NUVA) Scheduled to Post Earnings on Monday - October 16 at 5:26 AM logoNuVasive's (NUVA) Outperform Rating Reaffirmed at Leerink Swann - October 14 at 11:58 PM logoCowen and Company Reiterates "Buy" Rating for NuVasive, Inc. (NUVA) - October 14 at 11:26 PM logoNuVasive Receives Expanded FDA 510(k) Clearance For Innovative Magnetic Limb ... - October 14 at 6:19 AM logoNuVasive's (NUVA) PRECICE System Gets Expanded FDA Approval - October 14 at 6:19 AM logoBrokers Issue Forecasts for NuVasive, Inc.'s FY2017 Earnings (NUVA) - October 13 at 7:54 AM logoNuVasive (NUVA) Announces Expanded FDA 510(k) Clearance For Innovative Magnetic Limb Lengthening Technology - October 13 at 7:34 AM logoNuVasive Inc. (NUVA) Fell To A New Low For The Year - October 13 at 7:34 AM logoNuVasive Receives Expanded FDA 510(k) Clearance For Innovative Magnetic Limb Lengthening Technology - October 13 at 7:34 AM logoRobert W. Baird Reaffirms "Hold" Rating for NuVasive, Inc. (NUVA) - October 12 at 12:40 PM logoNuVasive sues former executive who moved to rival Alphatec - Reuters - October 12 at 7:39 AM logoBRIEF-NuVasive files lawsuit against Patrick S. Miles - Reuters - October 11 at 5:06 AM logoNuvasive Files Lawsuit Against Patrick S. Miles To Protect Corporate Assets And Stakeholders' Interests - PR Newswire (press release) - October 11 at 5:06 AM logoMorgan Stanley Reaffirms Equal Weight Rating for NuVasive, Inc. (NUVA) - October 7 at 12:00 PM logoNUVASIVE, INC. - - October 7 at 6:46 AM logoNeedham & Company LLC Reiterates Sell Rating for NuVasive, Inc. (NUVA) - October 6 at 11:14 PM logoNuvasive Announces Conference Call And Webcast Of Third Quarter 2017 Results - October 6 at 10:01 AM logoNuVasive Hosts 2nd Annual Spine Summit Event Focused On The Future Of Spine Care - October 5 at 12:47 PM logoNuVasive, Inc. (NUVA) Receives "Buy" Rating from BTIG Research - October 4 at 7:52 PM logoJefferies Group LLC Reaffirms Buy Rating for NuVasive, Inc. (NUVA) - October 3 at 6:38 PM logoNuVasive, Inc. (NUVA) Receives Average Rating of "Buy" from Analysts - September 30 at 8:34 PM logoHead to Head Review: NuVasive (NUVA) vs. The Competition - September 29 at 10:10 PM logoNuVasive's (NUVA) "Buy" Rating Reaffirmed at Piper Jaffray Companies - September 28 at 10:14 PM logoNuVasive Acquires Vetera Spine, Grows With Spinal Hardware - Nasdaq - September 28 at 12:26 PM logoINVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of NuVasive, Inc. Investors ... - Business Wire (press release) - September 23 at 8:54 AM logoNuVasive, Inc. (NUVA) Given "Buy" Rating at Gabelli - September 22 at 3:50 PM logoArons & Arons, LLC. Announces Investigation on Behalf of NuVasive, Inc. Investors - September 22 at 11:56 AM logoINVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of NuVasive, Inc. Investors (NUVA) - September 22 at 11:56 AM logoNuVasive acquires startup with Duke University roots - September 22 at 11:56 AM logoLeerink Swann Comments on NuVasive, Inc.'s Q3 2017 Earnings (NUVA) - September 21 at 7:56 AM logoNuVasive, Inc. (NUVA) Rating Reiterated by Leerink Swann - September 20 at 9:46 AM logoNuvasive Becomes Oversold (NUVA) - September 20 at 7:03 AM logoWhy Rite Aid, Synchronoss Technologies, and NuVasive Slumped Today - September 20 at 7:02 AM logoNuVasive's (NUVA) "Outperform" Rating Reiterated at Cowen and Company - September 18 at 5:08 PM logoWilliam Blair Weighs in on NuVasive, Inc.'s Q4 2017 Earnings (NUVA) - September 14 at 8:50 AM logoNuVasive Announces Commercial Launch Of LessRay System Designed To Significantly Reduce Radiation Exposure ... - PR Newswire (press release) - September 14 at 8:32 AM logoNuVasive Announces Commercial Launch Of LessRay System Designed To Significantly Reduce Radiation Exposure For Surgeons, Operating Room Staff And Patients - September 14 at 8:32 AM logoRoyal Bank Of Canada Reaffirms Buy Rating for NuVasive, Inc. (NUVA) - September 9 at 9:26 AM logoNuVasive Grows in Pediatric Deformity With New FDA Approval - Nasdaq - September 9 at 6:51 AM logoNuVasive Announces Vertera Spine Buyout, Boosts Implants Suite - Nasdaq - September 9 at 6:51 AM logoNuVasive Announces Acquisition Of Vertera Spine - PR Newswire (press release) - September 8 at 6:33 AM



NuVasive (NUVA) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.